IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 38911-0006US1

Applicant(s):	John W. ERICKSON et al.	Confirmation No. 8886
Appl. No.:	10/500,888	Art Unit: 1626
Filing Date:	December 1, 2004	Examiner: Unassigned
Title:	RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS	

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents is being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action that would be appropriate to antedate or otherwise remove as a competent reference any document that is determined to be a *prima facie* prior art reference against the claims of the present application.

RELEVANCE

The foregoing documents came to the Applicants' attention during a search of the corresponding international application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

TIMING/FEES

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

Date: August 2, 2005

By _____

HELLER EHRMAN LLP
1717 Rhode Island Avenue, NW
Washington, DC 20036
Telephone: (202) 912-2000
Facsimile: (202) 912-2020

Paul M. Booth
Registration No. 40,244
Attorney for Applicants

Customer No. 26633

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/500,888
Filing Date	December 1, 2004
First Named Inventor	ERICKSON et al.
Group Art Unit	1626
Examiner Name	Unassigned
Attorney Docket Number	38911-0006US1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	Document Number: Number - Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document: Country Code[3] - Number[4] - Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A01	WO 99/67254 A2	12/29/1999	The U.S. Government		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/500,888
Filing Date	December 1, 2004
First Named Inventor	ERICKSON et al.
Group Art Unit	1626
Examiner Name	Unassigned
Attorney Docket Number	38911-0006US1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	A02	ARUN K. GHOSH et al., "Potent HIV Protease Inhibitors Incorporating High-Affinity P2-Ligands and (R)-(Hydroxyethylamino) sulfonamide Isostere", Bioorganic & Medicinal Chemistry Letters, 1998, p. 687-690, Vol. 8	
	A03	ARUN K. GHOSH et al., "Structure Based Design: Novel Spirocyclic Ethers as Nonpeptidal P2-Ligands for HIV Protease Inhibitors", Bioorganic & Medicinal Chemistry Letters, 1998, pp. 979-982, Vol. 8	
	A04	ARUN K. GHOSH et al., "Structure-based design of non-peptide HIV protease inhibitors", IL FARMACO, January 2001, pp. 29-32, Vol. 56, No. ½	
	A05	KAZUHISA YOSHIMURA et al., "A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A282S) Mutation in the Protease Active Site", Journal of Virology, February 2002, pp. 1349-1358, Vol. 76, No. 3	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached.